Sandoz SDZ0.07%increase; green up pointing triangle Group shares fell Tuesday after the company said Chief Financial Officer Colin Bond would retire at the end of June and be replaced by Remco ...

Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who accused the company of conspiring with industry rivals to illegally fix prices.

Swiss generic and biosimilar manufacturer Sandoz on Thursday said it had entered into a $265 million settlement agreement in a price-fixing case in the United States.

MEDIA RELEASENOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN New USD 2.0 billion multi-currency revolving credit facility (RCF) in place to further strengthen Sandoz ...

Sandoz has signed a global collaboration agreement with Shanghai Henlius Biotech to commercialize a biosimilar of oncology therapy, ipilimumab (Bristol-Myers Squibb’s Yervoy).

In an unusual move, Sandoz is no longer cooperating with a U.K. industry trade group following a dispute over allegations that the company inappropriately marketed a biosimilar medicine. At issue ...

Sandoz Group said it would pay $275 million to settle claims from some plaintiffs in a generics drug pricing antitrust lawsuit in the U.S. The Swiss generics-medicine company said Tuesday that it ...

Keren Haruvi, President Sandoz North America, said: "Sandoz has achieved the first FDA approval for biosimilars to denosumab, a medicine that can address primary and secondary bone loss, such as ...

Sandoz has filed an antitrust lawsuit in the United States against Amgen, for extending and entrenching the dominant market position of its blockbuster medicine, Enbrel (etanercept).

A high-ranking Los Angeles police union official recently encouraged fellow LAPD cops to work in communities where local pols didn’t hate them and who “understand your worth." ...

Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 billion).

With an emphasis on biosimilars, Sandoz projects sales of its pipeline products to add $3 billion to its top line over the next five years.